Dongwha Pharm.Co.,Ltd

A000020

KR7000020008

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
8,720 ^KRW	-0.34%		+0.23%	-15.09%

2023	Cong Ty Co Phan Tscare announced that it has received KRW 37.442505601 billion in funding from Dongwha Pharm.Co.,Ltd	CI
2023	Oncocross Co., Ltd. announced that it has received KRW 15.00002592 billion in funding from InterVest Co., Ltd., Dongwha Pharm.Co.,Ltd and other investors	CI

Dongwha Pharm.Co.,Ltd authorizes a Buyback Plan.

July 19, 2017

The Board of Directors of Dongwha Pharm.Co.,Ltd has authorized a buyback plan on July 20, 2017.

Latest news about Dongwha Pharm.Co.,Ltd

Cong Ty Co Phan Tscare announced that it has received KRW 37.442505601 billion in funding from Dongwha Pharm.Co.,Ltd	Dec. 06	CI
Oncocross Co., Ltd. announced that it has received KRW 15.00002592 billion in funding from InterVest Co., Ltd., Dongwha Pharm.Co.,Ltd and other investors	23-10-26	CI
Oncocross Co., Ltd. announced that it expects to receive KRW 15.00002592 billion in funding from InterVest Co., Ltd., Dongwha Pharm.Co.,Ltd and other investors.	23-09-24	CI
Dongwha Pharm.Co.,Ltd signed an agreement to acquire 51% stake in TRUNGSONCARE CO., LTD for $30 million.	23-08-03	CI
Cong Ty Co Phan Tscare announced that it expects to receive KRW 39.115606503 billion in funding from Dongwha Pharm.Co.,Ltd	23-08-02	CI
Dongwha Pharm.Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Dongwha Pharm.Co.,Ltd agreed to acquire additional 11.18% stake in MEDYSSEY Co.,Ltd for KRW 4 billion.	20-10-04	CI
Dongwha Pharm.Co.,Ltd completed the acquisition of 53.3% stake in MEDYSSEY Co.,Ltd from Jongwook Jang, Min-kyung Jang, Ho-jeong Kim, Ji-won Jang and Seon-ok Kim.	20-09-23	CI
Dongwha Pharm.Co.,Ltd agreed to acquire 53.3% stake in MEDYSSEY Co.,Ltd from Jongwook Jang, Min-kyung Jang, Ho-jeong Kim, Ji-won Jang and Seon-ok Kim for KRW 19.6 billion.	20-07-23	CI
Philosys Co., Ltd. announced that it has received KRW 4 billion in funding from Dongwha Pharm.Co.,Ltd	18-04-25	CI
Philosys Co., Ltd. announced that it expects to receive KRW 4 billion in funding from Dongwha Pharm.Co.,Ltd	18-04-22	CI
Tranche Update on Dongwha Pharm.Co.,Ltd's Equity Buyback Plan announced on July 20, 2017.	17-09-24	CI
Dongwha Pharm.Co.,Ltd's Equity Buyback announced on July 20, 2017 has closed with 100,000 shares, representing 0.36% for KRW 875.76 million.	17-09-20	CI
Dongwha Pharm.Co.,Ltd announces an Equity Buyback for 100,000 shares.	17-07-20	CI
Dongwha Pharm.Co.,Ltd authorizes a Buyback Plan.	17-07-19	CI
Tranche Update on Dongwha Pharm Co.,Ltd.'s Equity Buyback Plan announced on January 30, 2015.	15-04-23	CI
Tranche Update on Dongwha Pharm Co.,Ltd.'s Equity Buyback Plan announced on January 30, 2015.	15-04-23	CI
Dongwha Pharm Co.,Ltd.’s Equity Buyback announced on January 30, 2015 has closed with 320,000 shares, representing 1.15% for KRW 2,349.54 million.	15-04-21	CI
Dongwha Pharm Co.,Ltd. announces an Equity Buyback for 320,000 shares.	15-01-29	CI
Dongwha Pharm Co.,Ltd. authorizes a Buyback Plan.	15-01-29	CI
Dong Wha Pharmaceuticals and Kyung Hee University Sign Technology Transfer Agreement	14-08-18	CI

DONGWHA PHARM.CO., LTD is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products consist of ethical drugs, including digestive system remedies, antibiotics, cardiovascular and metabolic disease treatments, non steroidal anti-inflammatory drugs, respiratory remedies, muscle relaxants, nervous system remedies, dermatological remedies and urinary system remedies, and over-the-counter (OTC) drugs, including cold remedies, dental remedies, dermatological remedies, hepatic protectors, nutrients, tonics, topical analgesics, anti-smoking agents and others. It also provides medicine raw materials, health food and drinks, as well as cosmetics. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
DONGWHA PHARM.CO.,LTD	-15.09%	176M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.27%	43.75B
OTSUKA HOLDINGS CO., LTD.	+27.47%	22.06B
SANDOZ GROUP AG	+15.11%	14.46B
CIPLA LIMITED	+12.33%	13.62B
ZYDUS LIFESCIENCES LIMITED	+38.36%	11.61B
ONO PHARMACEUTICAL CO., LTD.	-9.54%	6.9B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+9.64%	5.32B